VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2018 | The role of cabozantinib in renal cell carcinoma

Over the years, the treatment of renal cell carcinoma (RCC) has evolved rapidy. Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of the transition to immunotherapy from non-specific treatments for RCC. Dr McGregor focuses particularly on the role of cabozantinib in the first- and second-line treatment of RCC, highlighting promising results from recent clinical trials. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter